Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance strategies after 9-month budesonide capsules in IgA nephropathy
ChiCTR2600117860Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of budesonide in IgA nephropathy (IgAN), sponsored by Ruijin Hospital. Primary endpoint: Change in urinary protein from baseline. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
budesonide
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2600117860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117860.